The Regensight team has been an active part of The European Society of Cataract and Refractive Surgery (ESCRS) International Conference, which was held in Vienna from 8 to 11 September 2023.
At the startup’s stand, the Team has allowed the eye surgeons to experience first-hand the C4V CHROMO4VIS UV-A device; the experts have also shown the 6-month outcome of the ARGO multicenter randomized clinical trial, which aims is to validate the modern paradigm of personalized, precision and predictive medicine based upon theranostics (theraphy guided by advanced imaging diagnostics) for the treatment of keratoconus.
Regensight’s participation in the ESCRS Congress and the presentation of the new theranostics technology for treatment of keratoconus has aroused enormous interest and strong attention from operators of several countries, in particular where the prevalence of keratoconus and its social burden are high, as in the the Mediterranean area and the Middle Eeast.